NASDAQ:SANA Sana Biotechnology (SANA) Stock Forecast, Price & News $6.70 +0.49 (+7.89%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$6.08▼$6.8250-Day Range$3.11▼$7.5352-Week Range$2.99▼$9.55Volume1.11 million shsAverage Volume1.19 million shsMarket Capitalization$1.28 billionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Sana Biotechnology MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside49.3% Upside$10.00 Price TargetShort InterestBearish33.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$2.80 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector659th out of 981 stocksBiological Products, Except Diagnostic Industry107th out of 163 stocks 3.2 Analyst's Opinion Consensus RatingSana Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Sana Biotechnology has a forecasted upside of 49.3% from its current price of $6.70.Amount of Analyst CoverageSana Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted33.83% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 21.1, which indicates bearish sentiment.Change versus previous monthShort interest in Sana Biotechnology has recently increased by 0.04%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SANA. Previous Next 3.1 News and Social Media Coverage News SentimentSana Biotechnology has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.Search Interest16 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows3 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,796,366.00 in company stock.Percentage Held by Insiders34.90% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.12% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sana Biotechnology are expected to remain at ($1.49) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sana Biotechnology (NASDAQ:SANA) StockSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.Read More Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address SANA Stock News HeadlinesJune 1, 2023 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Stock Price Down 5.6%May 31, 2023 | finance.yahoo.comSana Biotechnology to Present at June 2023 Investor ConferencesJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 30, 2023 | msn.comSkyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On TuesdayMay 29, 2023 | americanbankingnews.comVentures Fund V. Gener Flagship Sells 82,000 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) StockMay 29, 2023 | americanbankingnews.comSana Biotechnology, Inc. (NASDAQ:SANA) Major Shareholder Ventures Fund V. Gener Flagship Sells 347,870 SharesMay 26, 2023 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Trading Down 6.2%May 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Sana Biotechnology (SANA)June 8, 2023 | Behind the Markets (Ad)Why did Biden repeal Trump's Executive Order?!" Why did Biden repeal Trump's Executive Order?! Within 10 days of taking office, President Trump signed "Executive Order 13771" in an effort to win the battle for what 60 minutes said could be "the most consequential discovery in biomedicine this century." So why did Biden repeal this? Click here to learn more >>> "May 22, 2023 | finance.yahoo.comWeekly biotech pulse: Sana, aTyr, Theseus to release fresh dataMay 17, 2023 | americanbankingnews.comSana Biotechnology Target of Unusually Large Options Trading (NASDAQ:SANA)May 11, 2023 | msn.comUnusual Call Option Trade in Sana Biotechnology (SANA) Worth $29.48KMay 11, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Sana Biotechnology, Inc. Decreased by HC Wainwright (NASDAQ:SANA)May 11, 2023 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Shares Up 8.5%May 9, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Sana Biotechnology (SANA)May 8, 2023 | msn.comSana Biotechnology Non-GAAP EPS of -$0.43May 8, 2023 | finance.yahoo.comSana Biotechnology Reports First Quarter 2023 Financial Results and Business UpdatesMay 8, 2023 | finance.yahoo.comSana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully FunctionalMay 4, 2023 | americanbankingnews.comSana Biotechnology, Inc. Forecasted to Post Q1 2023 Earnings of ($0.35) Per Share (NASDAQ:SANA)May 3, 2023 | finance.yahoo.comSana Biotechnology to Present at May 2023 Investor ConferencesMay 3, 2023 | finance.yahoo.comWall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to TradeMay 2, 2023 | tmcnet.comSana Biotechnology Announces the Acceptance of Six AbstractsMay 2, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Sana Biotechnology (SANA) with Neutral RecommendationMay 2, 2023 | msn.comSana Biotech initiated Neutral at H.C. Wainwright on valuationMay 2, 2023 | finance.yahoo.comIs Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?May 2, 2023 | finance.yahoo.comSana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingMay 2, 2023 | bizjournals.comSana fills 2 senior roles as the Seattle biotech shifts focusSee More Headlines SANA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SANA Company Calendar Last Earnings3/16/2023Today6/08/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SANA CUSIPN/A CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees383Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+49.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.06% Return on Assets-39.12% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.62 per share Price / Book2.56Miscellaneous Outstanding Shares191,500,000Free Float124,667,000Market Cap$1.28 billion OptionableNot Optionable Beta0.71 Key ExecutivesDr. Steven D. Harr M.D. (Age 53)Pres, CEO & Director Comp: $1.19MDr. Richard C. Mulligan Ph.D. (Age 68)Exec. Vice Chairman & Head of SanaX Mr. Nathan Hardy M.B.A. (Age 47)Exec. VP & CFO Comp: $683.49kDr. Sunil Agarwal M.D. (Age 53)Exec. VP, Head of Devel. & Chief Medical Officer Comp: $728.45kBrittany MccleeryAccounting Mang.Dr. Edward Rebar Ph.D. (Age 55)Sr. VP & CTO Mr. Bernard J. Cassidy J.D. (Age 68)Exec. VP & Gen. Counsel Ms. Robin Andrulevich (Age 57)Exec. VP & Chief People Officer Mr. Paul Brunetta M.D.Sr. VP and Head of Clinical & Translational ScienceMs. Donna Dambach D.V.M.Ph.D., Sr. VP & Head of Devel. SciencesMore ExecutivesKey CompetitorsAdaptive BiotechnologiesNASDAQ:ADPTInhibrxNASDAQ:INBXReplimune GroupNASDAQ:REPLScilexNASDAQ:SCLXKymera TherapeuticsNASDAQ:KYMRView All CompetitorsInsiders & InstitutionsVentures Fund V Gener FlagshipSold 82,000 sharesTotal: $510,860.00 ($6.23/share)ProShare Advisors LLCSold 3,513 shares on 5/26/2023Ownership: 0.012%Ventures Fund V Gener FlagshipSold 347,870 sharesTotal: $2.29 M ($6.57/share)Ameriprise Financial Inc.Bought 31,595 shares on 5/22/2023Ownership: 0.040%JPMorgan Chase & Co.Bought 66,301 shares on 5/18/2023Ownership: 1.275%View All Insider TransactionsView All Institutional Transactions SANA Stock - Frequently Asked Questions Should I buy or sell Sana Biotechnology stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SANA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SANA, but not buy additional shares or sell existing shares. View SANA analyst ratings or view top-rated stocks. What is Sana Biotechnology's stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year price objectives for Sana Biotechnology's stock. Their SANA share price forecasts range from $6.00 to $13.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 49.3% from the stock's current price. View analysts price targets for SANA or view top-rated stocks among Wall Street analysts. How have SANA shares performed in 2023? Sana Biotechnology's stock was trading at $3.95 at the beginning of 2023. Since then, SANA stock has increased by 69.6% and is now trading at $6.70. View the best growth stocks for 2023 here. When is Sana Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our SANA earnings forecast. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) announced its quarterly earnings results on Thursday, March, 16th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. What ETFs hold Sana Biotechnology's stock? ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include SPDR S&P Biotech ETF (XBI), iShares Genomics Immunology and Healthcare ETF (IDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). When did Sana Biotechnology IPO? (SANA) raised $322 million in an IPO on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO. What is Sana Biotechnology's stock symbol? Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA." Who are Sana Biotechnology's major shareholders? Sana Biotechnology's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.68%), FMR LLC (4.78%), BlackRock Inc. (4.07%), State Street Corp (2.97%), Price T Rowe Associates Inc. MD (2.36%) and JPMorgan Chase & Co. (1.28%). Insiders that own company stock include Christian Hordo, James J Macdonald, Joshua H Bilenker, Patrick Y Yang and Ventures Fund V Gener Flagship. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sana Biotechnology's stock price today? One share of SANA stock can currently be purchased for approximately $6.70. How much money does Sana Biotechnology make? Sana Biotechnology (NASDAQ:SANA) has a market capitalization of $1.28 billion. The company earns $-269,480,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. How many employees does Sana Biotechnology have? The company employs 383 workers across the globe. How can I contact Sana Biotechnology? Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The official website for the company is sana.com. The company can be reached via phone at 206-701-7914 or via email at investor.relations@sana.com. This page (NASDAQ:SANA) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.